Alphyn plans to present the full results of this trial at a scientific conference and submit a paper for publication in a peer-reviewed journal.

Alphyn Biologics’ topical AB-101a met all of its primary endpoints in Phase 2a clinical trial of mild-to-moderate atopic dermatitis (AD). 

Alphyn plans to present the full results of this trial at a scientific conference and submit a paper for publication in a peer-reviewed journal.

The randomized, vehicle-controlled, double-blind trial is evaluating the treatment protocol of AB-101a across multiple sites using standard scales for assessing AD. The trial, conducted in Australia, enrolled 41 AD patients, and treatment was evaluated after four weeks.

"As a physician who treated 15 percent of the patients in the clinical trial, I am encouraged by the results with AB-101a," says Dr. Stephen Shumack, Clinical Associate Professor Dermatology, University of Sydney, and Principal Investigator at St George Dermatology & Skin Cancer Centre, in a news release. "I look forward to future trials and gaining a better understanding of AB-101a's potential benefits for patients."

Enrollment is ongoing in the second cohort of the Phase 2a clinical trial. This cohort is investigating the unique ability of AB-101a to treat the infected component of AD in AD patients who are suffering from bacterial infections, including Staphylococcus aureus and MRSA.  Alphyn anticipates AB-101a will be effective in treating non-infected AD and infected AD. 

"Patients with mild-to-moderate atopic dermatitis suffer considerably from the symptoms of this often-debilitating disease, yet available treatments come with side effects and safety concerns," says Alphyn CEO Neal Koller. "We are excited by these results and look forward to the results of our ongoing cohort treating infected AD. We plan to further study AB-101a in a Phase 2b/3 trial this year in conjunction with a Series B financing."